VEXT SCIENCE INC - VEXTF STOCK NEWS

Vext Science announced its Q1 2024 financial results, highlighting a revenue of $8.4 million, compared to $9.1 million in Q1 2023. The adjusted EBITDA stood at $1.9 million, a decrease from $2.9 million in Q1 2023. The EBITDA margin improved to 23.3% from 6.5% in Q4 2023. The company is preparing for the anticipated adult-use program in Ohio, leveraging its vertically-integrated operations. A $2 million standby credit facility has been secured to support operations and expansion in Ohio. CEO Eric Offenberger emphasized the potential growth in Ohio despite consumer challenges in Arizona. The company plans to enhance cash flow and shareholder returns with modest capital expenditures and strategic financial flexibility.

Vext Science (CSE: VEXT, OTCQX: VEXTF), a U.S.-based cannabis operator in Arizona and Ohio, announced it will release its Q1 2024 financial results on May 29, 2024, before market open.

The results will cover the quarter ended March 31, 2024.

A conference call and webcast will follow at 8:00 a.m. ET on the same day.

Dial-in numbers for the call are +1-647-484-8814 or 1-844-763-8274, with a replay available until June 12, 2024, at +1-604-674-8052 or 1-855-669-9658, using conference ID 10023534.

Webcast access is provided through https://www.gowebcasting.com/13356. For further details, contact investors@vextscience.com.

Vext Science, Inc. reported a revenue of $34.8 million for 2023 with Adjusted EBITDA of $5.5 million. The company is set to launch an adult-use program in Ohio for significant growth. Ohio expansion includes a cultivation facility, manufacturing facility, and four dispensaries. Despite market challenges, Vext performed well in Q4, positioning itself for growth in Ohio's $4 billion cannabis market. Recent acquisitions and debt conversions indicate strategic moves for Vext's expansion.

Vext Science, Inc. announces new date for Q4 and fiscal 2023 financial results release. The company will release its financial results for the period ended December 31, 2023, on May 10, 2024, and host a conference call and webcast on the same day at 1:00 p.m. ET.

Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) announces a delay in the filing of its annual financial statements for 2023, related management discussions, and officer certifications. The delay is due to a recent auditor change and complex accounting treatment of Q4 2023 transactions. The company has postponed its conference call scheduled for April 25, 2024, until the filings are complete. Vext is actively working with auditors to complete the filings by May 10, 2024, and has applied for a management cease trade order to restrict trading until filings are submitted.

Vext Science, Inc. (VEXTF) to announce financial results for Q4 and Fiscal 2023 on April 25, 2024. The U.S.-based cannabis operator with operations in Arizona and Ohio will host a conference call to discuss the results.

Vext Science, Inc. completes the acquisition of real property associated with a cannabis dispensary in Athens, Ohio as part of the Ohio Expansion Transaction. The Company paid $2.6 million for the acquisition, with $0.9 million in cash and a $1.7 million promissory note at 7.0% interest repayable over 10 years. The acquisition is expected to be completed by the end of 2024.

Vext Science, Inc. changes its auditor from BF Borgers CPA PC to Reliant CPA due to enforcement actions by the Canadian Public Accountability Board. The Former Auditor resigned, and the Successor Auditor was appointed effective March 8, 2024.

Vext Science, Inc. receives regulatory approval and closes debenture conversion transaction. Insider shareholder Sopica Special Opportunities Fund Limited acquires 24,087,500 common shares.